RCM
MBX

RA Capital Management’s MBX Biosciences MBX Stock Holding History

RA Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-377,841
Closed -$4.31M – 75
2025
Q2 		$4.31M Sell
377,841
-1,133,493
-75% -$11.5M 0.07% 59
2025
Q1 		$11.2M Hold
1,511,334
– – 0.19% 63
2024
Q4 		$27.9M Hold
1,511,334
– – 0.37% 46
2024
Q3 		$39.3M Buy
+1,511,334
New +$34.6M 0.45% 44

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RA Capital Management's MBX Position: Q3 2025 in Review

RA Capital Management sold out of MBX Biosciences (MBX) in Q3 2025, closing a stake of 377,841 shares — an estimated $4.31M sold.

RA Capital Management first reported a position in MBX in Q3 2024 and held it in 4 quarters. The position peaked at $39.3M in Q3 2024. 118 funds tracked by Wall St. Rank hold MBX as of Q3 2025.

  • RA Capital Management reported no remaining MBX Biosciences position as of Q3 2025 after selling out during the quarter.
  • RA Capital Management sold 377,841 MBX Biosciences shares in Q3 2025, an estimated $4.31M.
  • RA Capital Management first reported a position in MBX Biosciences in Q3 2024 and held it in 4 quarters.
  • RA Capital Management's MBX Biosciences position peaked at $39.3M in Q3 2024.
  • 118 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2025.

Based on RA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.